Examination of survivin expression in 50 chordoma specimens—A histological and in vitro study. Issue 5 (13th March 2015)

• Record Type: Journal Article
• Authors: Froehlich, Elke V.; Rinner, Beate; Deutsch, Alexander J. A.; Meditz, Katharina; Knausz, Heike; Troppan, Katharina; Scheipl, Susanne; Wibmer, Christine; Leithner, Andreas; Liegl, Bernadette; Lohberger, Birgit
• Is Part Of: Journal of orthopaedic research. Volume 33:Issue 5(2015:May)
• Page Start: 771
• Page End: 778
• Publication Date: 2015-03-13
• Subjects: chordoma -- survivin -- YM155 -- cell cycle; Orthopedics -- Periodicals; Musculoskeletal system -- Periodicals; 616.7
• DOI: 10.1002/jor.22819
• Languages: English
• ISSNs: 0736-0266

Abstract

ABSTRACT: Chordomas mainly arise along the axial skeleton and are characterized by their slow but destructive growth. Prognosis and quality of life are poor because treatment options are mainly limited to surgery and radiotherapy. Survivin, a member of the apoptosis inhibitor protein family, functions as a key regulator of mitosis and programmed cell death, and is overexpressed in many tumor types. The aim of this study was to determine the role of survivin in chordomas. Survivin expression was investigated in 50 chordoma samples and three chordoma cell lines using immunohistochemistry. The intensity of immunostaining was evaluated in regard to the development of recurrences. The immunohistochemical results were correlated with clinical parameters like gender, age, tumor size, and location and were performed in primary chordomas as well as in recurrent lesions. Furthermore, survivin knockdown experiments on chordoma cell lines were performed. YM155 decreased the growth behavior of chordoma cells dose‐ and time dependently. Transient knockdown of survivin led to a G2/M arrest, decreased proliferation, consistently induced an increase of polyploidy and morphological changes, and induced apoptosis. The resultant data from this study suggest that survivin plays a cell cycle‐progressive role in chordomas. Hence, regulation of survivin by YM155 is a promising new target for the development of new therapeutic drugs. © 2015 Orthopaedic Research Society. Published by Wiley Periodicals, Inc. J Orthop Res 33:771–778, 2015.